Shanghai MicroPort MedBot (Group) Co., Ltd. (2252.HK)
- Previous Close
19.200 - Open
19.400 - Bid 18.580 x --
- Ask 18.600 x --
- Day's Range
18.380 - 19.780 - 52 Week Range
6.030 - 25.650 - Volume
3,386,876 - Avg. Volume
10,523,141 - Market Cap (intraday)
18.695B - Beta (5Y Monthly) 1.66
- PE Ratio (TTM)
-- - EPS (TTM)
-0.710 - Earnings Date Mar 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.14
Shanghai MicroPort MedBot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China. The company offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; SkyWalker, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. It also offers trans-bronchial surgical robots for trans-bronchial diagnosis and treatment. In addition, the company is involved in the manufacture of parts of surgical robot devices; research, development, assembly, and distribution of surgical robot devices; and research and development of system, as well as investment activities. The company was founded in 2014 and is headquartered in Shanghai, China. Shanghai MicroPort MedBot (Group) Co., Ltd. operates as a subsidiary of Shanghai Latent Artificial Intelligence Co., Ltd.
www.medbotsurgical.comRecent News: 2252.HK
View MorePerformance Overview: 2252.HK
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2252.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2252.HK
View MoreValuation Measures
Market Cap
19.32B
Enterprise Value
19.40B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
67.14
Price/Book (mrq)
64.61
Enterprise Value/Revenue
70.18
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-249.72%
Return on Assets (ttm)
-21.91%
Return on Equity (ttm)
-170.42%
Revenue (ttm)
257.25M
Net Income Avi to Common (ttm)
-642.41M
Diluted EPS (ttm)
-0.710
Balance Sheet and Cash Flow
Total Cash (mrq)
612.23M
Total Debt/Equity (mrq)
268.29%
Levered Free Cash Flow (ttm)
--